Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;28(10):1316-1318.
doi: 10.1016/j.cmi.2022.06.032. Epub 2022 Jul 16.

Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization

Vibeke Klastrup  1 , Nina Breinholt Stærke  1 , Ole Schmeltz Søgaard  2
Affiliations

Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization

Vibeke Klastrup et al. Clin Microbiol Infect. 2022 Oct.
No abstract available

Keywords: COVID-19; Heterologous; Homologous vaccine.

PubMed Disclaimer

References

    1. European Medicines Agency COVID-19 vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-pos...
    1. Paterlini M. Covid-19: Sweden, Norway, and Finland suspend use of Moderna vaccine in young people “as a precaution. BMJ. 2021;375:n2477. - PubMed
    1. Pereson MJ, Amaya L, Neukam K, Bare P, Echegoyen N, Badano MN et al. Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination induces a stronger humoral response than homologous Sputnik V in a real-world data analysis. Clin Microbiol Infect 2022;28:1126–33. doi: 10.1016/j.cmi.2022.03.003. - DOI - PMC - PubMed
    1. Liu X., Shaw R.H., Stuart A.S.V., Greenland M., Aley P.K., Andrews N.J., et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856–869. - PMC - PubMed
    1. Barros-Martins J., Hammerschmidt S.I., Cossmann A., Odak I., Stankov M.V., Morillas Ramos G., et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27:1525–1529. - PMC - PubMed